Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Mar;21(3):128-132.
doi: 10.1089/dia.2018.0374. Epub 2019 Jan 25.

Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems

John B Welsh  1 , Peggy Gao  1 , Mark Derdzinski  1 , Sarah Puhr  1 , Terri Kang Johnson  1 , Tomas C Walker  1 , Claudia Graham  1
Affiliations
Comparative Study

Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems

John B Welsh et al. Diabetes Technol Ther. 2019 Mar.

Abstract

Background: Accuracy and feature sets of continuous glucose monitoring (CGM) systems may influence device utilization and outcomes. We compared clinical trial accuracy and real-world utilization and effectiveness of two different CGM systems.

Materials and methods: Separately conducted accuracy studies of a fifth-generation and a sixth-generation CGM system involved 50 and 159 adults, respectively. For between-system performance comparisons, propensity score methods were utilized to balance cohort characteristics. Real-world outcomes were assessed in 10,000 anonymized patients who had switched from the fifth-generation to the sixth-generation system and had used connected mobile devices to upload data from both systems, allowing pairwise comparisons of device utilization and glucose concentration distributions.

Results: Propensity score-adjusted mean absolute relative differences for the fifth- and sixth-generation systems were 9.0% and 9.9%, and the percentages of values within ±20%/20 mg/dL were 93.1% and 92.5%, respectively. The sixth-generation system, but not the fifth-generation system, met accuracy criteria for interoperable CGM systems. Both systems had high real-world utilization rates (93.8% and 95.3% in the fifth- and sixth-generation systems, respectively). Use of the sixth-generation system was associated with fewer glucose values <55 mg/dL (<3.1 mmol/L) (0.7% vs. 1.1%, P < 0.001) and more values 70-180 mg/dL (3.9-10.0 mmol/L) (57.3% vs. 56.0%, P < 0.001) than the fifth-generation system.

Conclusions: CGM performance outcomes can be compared through the propensity score analysis of clinical trial data and pairwise comparisons of real-world data. The systems compared here had nearly equivalent accuracy and utilization rates. Longer term biochemical and psychosocial benefits observed with the fifth-generation system are also expected with the sixth-generation system.

Keywords: Continuous glucose monitoring; Dexcom G5; Dexcom G6; Propensity scoring; Real-world evidence..

PubMed Disclaimer

Conflict of interest statement

The authors are employees of Dexcom, Inc.

References

    1. Beck RW, Riddlesworth T, Ruedy K, et al. : Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 2017;317:371–378 - PubMed
    1. Beck RW, Riddlesworth TD, Ruedy K, et al. : Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med 2017;167:365–374 - PubMed
    1. Heinemann L, Freckmann G, Ehrmann D, et al. : Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018;391:1367–1377 - PubMed
    1. Olafsdottir AF, Polonsky W, Bolinder J, et al. : A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3). Diabetes Technol Ther 2018;20:274–284 - PMC - PubMed
    1. Polonsky WH, Hessler D, Ruedy KJ, et al. : The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017;40:736–741 - PubMed

Publication types